“During the assessment of cannabidiol (CBD) as a novel food, in 2022 the NDA Panel identified significant data gaps. Concerns focused on potential adverse effects on the liver, gastrointestinal tract, endocrine, nervous and reproductive systems,” the European Food Safety Authority started. It suggested a provisional ‘safe’ dose.
Search
News Archives
News Signup
FREE: daily or weekly news supporting freedom from dependency
Journal signup
FREE: print journal and emag supporting freedom from dependency
Conference savings
MONEY OFF: for signups
Support our work
To support us giving the recovery field FREE daily news+research, FREE library, FREE journal and subsidised conference training, click the secure Donate link. THANK YOU!
Recent News
